Maia Kipiani1, Veriko Mirtskhulava2, Nestani Tukvadze1, Matthew Magee3, Henry M Blumberg4, Russell R Kempker5. 1. National Center for Tuberculosis and Lung Diseases. 2. Department of Public Health and Epidemiology, Davit Tvildiani Medical University, Tbilisi. 3. Department of Epidemiology and Biostatistics, School of Public Heath, Georgia State University Departments of Epidemiology and Global Health, Emory Rollins School of Public Health. 4. Departments of Epidemiology and Global Health, Emory Rollins School of Public Health Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 5. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Abstract
BACKGROUND: There are limited data on the clinical impact of rapid diagnostic tests to detect multidrug-resistant tuberculosis (MDR-TB). We sought to determine whether the use of a molecular diagnostic test to detect MDR-TB improves clinical outcomes. METHODS: A quasi-experimental study was conducted to analyze the impact of the Genotype MTBDRplus assay on clinical outcomes among patients with culture-confirmed pulmonary MDR-TB. Patients received treatment at the National Center for Tuberculosis and Lung Diseases in Tbilisi, Georgia. Time to MDR-TB treatment initiation, culture conversion, and infection control measures were compared to a time period prior to the implementation of the molecular test. RESULTS: Of 152 MDR-TB patients, 72 (47%) were from prior to and 80 (53%) following implementation of the MTBDRplus assay ("post-implementation group"). Patients in the post-implementation group initiated a second-line treatment regimen more rapidly than those in the pre-implementation group (18.2 vs 83.9 days, P < .01). Among patients admitted to a "drug-susceptible" tuberculosis ward, those from the post-implementation group spent significantly fewer days on the drug-susceptible ward compared to patients in the pre-implementation group (10.0 vs 58.3 days, P < .01). Among patients with 24 weeks follow-up (n = 119), those in the post-implementation group had a higher rate of culture conversion at 24 weeks (86% vs 63%, P < .01) and a more rapid rate of time to culture conversion (adjusted hazard ratio [aHR] 4.15, 95% confidence interval [CI], 2.5-6.9). CONCLUSIONS: The implementation of a rapid molecular diagnostic test led to significant clinical improvements including reduced time to initiation of MDR-TB treatment, culture conversion, and improved infection control practices.
BACKGROUND: There are limited data on the clinical impact of rapid diagnostic tests to detect multidrug-resistant tuberculosis (MDR-TB). We sought to determine whether the use of a molecular diagnostic test to detect MDR-TB improves clinical outcomes. METHODS: A quasi-experimental study was conducted to analyze the impact of the Genotype MTBDRplus assay on clinical outcomes among patients with culture-confirmed pulmonary MDR-TB. Patients received treatment at the National Center for Tuberculosis and Lung Diseases in Tbilisi, Georgia. Time to MDR-TB treatment initiation, culture conversion, and infection control measures were compared to a time period prior to the implementation of the molecular test. RESULTS: Of 152 MDR-TBpatients, 72 (47%) were from prior to and 80 (53%) following implementation of the MTBDRplus assay ("post-implementation group"). Patients in the post-implementation group initiated a second-line treatment regimen more rapidly than those in the pre-implementation group (18.2 vs 83.9 days, P < .01). Among patients admitted to a "drug-susceptible" tuberculosis ward, those from the post-implementation group spent significantly fewer days on the drug-susceptible ward compared to patients in the pre-implementation group (10.0 vs 58.3 days, P < .01). Among patients with 24 weeks follow-up (n = 119), those in the post-implementation group had a higher rate of culture conversion at 24 weeks (86% vs 63%, P < .01) and a more rapid rate of time to culture conversion (adjusted hazard ratio [aHR] 4.15, 95% confidence interval [CI], 2.5-6.9). CONCLUSIONS: The implementation of a rapid molecular diagnostic test led to significant clinical improvements including reduced time to initiation of MDR-TB treatment, culture conversion, and improved infection control practices.
Authors: Anthony D Harris; Douglas D Bradham; Mona Baumgarten; Ilene H Zuckerman; Jeffrey C Fink; Eli N Perencevich Journal: Clin Infect Dis Date: 2004-05-12 Impact factor: 9.079
Authors: Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg Journal: Int J Infect Dis Date: 2012-03-17 Impact factor: 3.623
Authors: Linda M Parsons; Akos Somoskövi; Cristina Gutierrez; Evan Lee; C N Paramasivan; Alash'le Abimiku; Steven Spector; Giorgio Roscigno; John Nkengasong Journal: Clin Microbiol Rev Date: 2011-04 Impact factor: 26.132
Authors: Neel R Gandhi; Darren Weissman; Prashini Moodley; Melissa Ramathal; Inga Elson; Barry N Kreiswirth; Barun Mathema; Elena Shashkina; Richard Rothenberg; Anthony P Moll; Gerald Friedland; A Willem Sturm; N Sarita Shah Journal: J Infect Dis Date: 2012-11-19 Impact factor: 5.226
Authors: Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: E V Kurbatova; V M Gammino; J Bayona; M C Becerra; M Danilovitz; D Falzon; I Gelmanova; S Keshavjee; V Leimane; C D Mitnick; M I Quelapio; V Riekstina; A Taylor; P Viiklepp; M Zignol; J P Cegielski Journal: Int J Tuberc Lung Dis Date: 2012-10 Impact factor: 2.373
Authors: Nestani Tukvadze; Russell R Kempker; Iagor Kalandadze; Ekaterina Kurbatova; Michael K Leonard; Rusudan Apsindzelashvili; Nino Bablishvili; Maia Kipiani; Henry M Blumberg Journal: PLoS One Date: 2012-02-09 Impact factor: 3.240
Authors: N Bablishvili; N Tukvadze; E Shashkina; B Mathema; N R Gandhi; H M Blumberg; R R Kempker Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191
Authors: M Buziashvili; V Mirtskhulava; M Kipiani; H M Blumberg; D Baliashvili; M J Magee; J J Furin; N Tukvadze; R R Kempker Journal: Int J Tuberc Lung Dis Date: 2019-09-01 Impact factor: 2.373
Authors: L Mikiashvili; M Kipiani; M C Schechter; Z Avaliani; N Kiria; R R Kempker Journal: Int J Tuberc Lung Dis Date: 2020-04-01 Impact factor: 2.373
Authors: N N Abanda; J Y Djieugoué; V S Khadka; E W Pefura-Yone; W F Mbacham; G Vernet; V M Penlap; Y Deng; S I Eyangoh; D W Taylor; R G F Leke Journal: Clin Microbiol Infect Date: 2017-12-05 Impact factor: 8.067
Authors: C S Feliciano; M M P Nascimento; L M P Anselmo; R H C Pocente; F Bellissimo-Rodrigues; V R Bollela Journal: Braz J Med Biol Res Date: 2015-06-30 Impact factor: 2.590
Authors: Russell R Kempker; Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew J Magee; Henry M Blumberg Journal: Emerg Infect Dis Date: 2015-06 Impact factor: 6.883